See how it's done: GSK beats data access path
This article was originally published in Scrip
GlaxoSmithKline, now the industry leader on the clinical trial transparency front, has given more details of its system for providing raw patient-level data to researchers for further analysis, including strict controls over who can access the data and to what end. It has also named the members of the panel that will vet research proposals.
You may also be interested in...
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.
At the end of the Brexit transition period, the UK will be charting its own course through the often choppy seas of medicines regulation. While it plans to retain the existing EU rules that have been transposed into domestic legislation, it also wants the freedom to tailor its regulations in areas like clinical trials, advanced therapies and product labeling.